Search Results
SOPHIA: Margetuximab and chemo versus trastuzumab and chemo in HER2 positive MBC after prior ant...
Dr. Pegram on Margetuximab Plus Chemo in HER2+ Breast Cancer
SOPHIA Trial in R/R HER2+ mBC
Dr. Rugo on the Phase III SOPHIA Trial in HER2+ Breast Cancer
Margetuximab for the treatment of HER2-positive breast cancer
Latest updates in HER2-positive metastatic breast cancer: The NALA and SOPHIA trials
Margetuximab for the Treatment of HER2+ Breast Cancer
Sequencing novel HER2-targeted therapies in metastatic breast cancer
Sara M. Tolaney, MD, MPH, provides an overview of the results from the SOPHIA trial
Neelima Denduluri, MD, elaborates on the SOPHIA trial data in HER+ metastatic breast cancer
Margenza (Margetuximab)- treatment of adult patients with metastatic HER2- positive breast cancer
At ASCO 2019, Dr. Hope Rugo presents on results of the SOPHIA breast cancer study
